natalizumab
biogen
['natalizumab']
teunissen: snfl does not differentiate progressors versus non-progressors in patients treated with natalizumab (pira). but they found other candidate proteins that do correlate with clinical or mri progression il15, cr2, chit1 and mog are promising.
#ectrims2022 
Professor Dr Bart Van Wijmeersch
Neurologist, Immunologist
#MultipleSclerosis Expert
@ University MS Centre, Hasselt-Pelt, Belgium